Skip to main content

Table 5 Adjusted models of androgen levels and 12- and 36-month outcomes stratified by the older affected sibling’s sex

From: Umbilical cord blood androgen levels and ASD-related phenotypes at 12 and 36 months in an enriched risk cohort study

Androgensa Older affected sibling’s sex Outcomes
   12-month AOSI 36-month SRS
   Beta 95% CI P P b Beta 95% CI P P b
ln(T) Female (n = 22) 0.91 (0.20,1.63) 0.02 0.008 0.61 (0.27,0.94) 0.001 0.006
  Male (n = 115) 0.08 (−0.16, 0.32) 0.50   −0.08 (−0.30,0.14) 0.47  
ln(A4) Female (n = 22) 0.22 (−1.88,2.33) 0.82 0.84 1.10 (−0.07,2.28) 0.06 0.06
  Male (n = 115) 0.05 (−0.22,0.33) 0.70   −0.23 (−0.48,0.02) 0.07  
ln(DHEA) Female (n = 22) 0.39 (−0.40,1.18) 0.32 0.36 0.18 (−0.26,0.61) 0.40 0.68
  Male (n = 115) 0.02 (−0.20,0.24) 0.86   −0.06 (−0.26,0.14) 0.57  
  1. ln natural log transformed
  2. aRobust regression models of loge-transformed testosterone (T), androstenedione (A4), and dehydroepiandrostenedione (DHEA) with total loge (AOSI + 1) and loge (SRS raw) adjusted for infant sex, gestational age and maternal age. Outcome measures are 12-month Autism Observation Scales for Infants (AOSI) total score and 36-month Social Responsiveness Scale (SRS) total raw score
  3. bInteraction P value comes from a model including both subject sexes including covariates, hormone variable, subject sex, older affected sibling sex and older affected sibling sex hormone interaction